adalimumab-adaz — CareFirst (Caremark)
immune checkpoint inhibitor-related toxicity with inflammatory arthritis
Initial criteria
- Member has moderate or severe immunotherapy-related inflammatory arthritis
- AND inadequate response to corticosteroids or a conventional synthetic drug (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine)
- OR intolerance/contraindication to corticosteroids and a conventional synthetic drug
Approval duration
12 months